)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics (LABT) investor relations material
Lakewood-Amedex Biotherapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary14 Aug, 2026
Executive summary
Completed $7.5 million Series C Convertible Preferred Stock financing, raising $6.8 million net proceeds and strengthening liquidity.
Listed common stock on Nasdaq Capital Market, simplifying capital structure via conversion of preferred stock and convertible debt.
Focus shifted to advancing clinical development, particularly the planned Phase 2a study for lead product Nu-3.
Financial highlights
Net loss was $3.77 million for Q2 2026, compared to $0.66 million in Q2 2025; net loss for the six months was $4.70 million, up from $1.20 million year-over-year.
Operating expenses rose to $3.79 million in Q2 2026 from $0.64 million in Q2 2025, driven by higher R&D and G&A costs.
Cash, cash equivalents, and investments totaled $4.6 million at June 30, 2026, up from $0.24 million at year-end 2025.
Working capital improved to $4.2 million at June 30, 2026, from a deficit of $2.1 million at December 31, 2025.
Outlook and guidance
Current liquidity expected to fund operations into Q1 2027; additional capital will be required to complete clinical development and commercialization.
Management plans to pursue further equity or debt financing, partnerships, or grants.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lakewood-Amedex Biotherapeutics
- Shareholders will vote on director elections, capital structure changes, and governance matters.LABT
Proxy filing - Virtual meeting to vote on directors, share increase, reverse split, equity plan, and auditor.LABTProxy filing
- Key votes include board elections, share authorization, reverse split, and equity plan expansion.LABTProxy filing
- Bisphosphocins advance as a promising antimicrobial platform, with phase II DFU trial readout expected in 2024.LABTLife Sciences Virtual Investor Forum
- Nu-3 gel, a novel Bisphosphocin® antimicrobial, advances in clinical trials for resistant iDFU.LABTCorporate presentation
- Q1 net loss increased to $0.9M; Series C financing closed, but more capital needed for operations.LABTQ1 2026
- Experienced management and independent board with strong governance and equity incentives.LABTRegistration filing
- Biotech with novel antimicrobials seeks Nasdaq direct listing; no proceeds to company, high risk.LABTRegistration filing
- Direct listing registers 4.7M shares for resale; biotech targets AMR with novel antimicrobials.LABTRegistration filing
Next Lakewood-Amedex Biotherapeutics earnings date
Q3 202613 Nov, 2026
Lakewood-Amedex Biotherapeutics
Next Lakewood-Amedex Biotherapeutics earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage